NCT01765127View on ClinicalTrials.gov

An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)

CompletedOBSERVATIONAL
Enrollment

122

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

January 31, 2018

Conditions
Bipolar I Disorder
Trial Locations (1)

SO31 1AA

Drug Safety Research Unit (for data collation and analysis only), Southampton

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Professor Saad Shakir

OTHER

NCT01765127 - An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest) | Biotech Hunter | Biotech Hunter